Loading the company…
Loading the company…
㈜다우바이오메디카
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2006. Industry: Wholesale & Retail. Revenue for 2025 was ₩56.3bn. It has 49 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2022-05-02 · latest registration 2026-03-18 · newest first
본 개시의 일 실시예는 NGS 분석방법에 의하여 임의의 서열에 대한 리드에 대한 정보를 획득하고, 기준서열(reference sequence)을 기준으로 상기 획득된 리드들 중 동일한 insertion 서열을 갖는 리드를 선별; 및 b)동일한 soft-clipped bases를 갖는 리드들을 선별하고, 상기 선별된 리드들의 soft-clipped bases 서열 및 insertion 서열의 일부 또는 전부를 포함하는 부위를 씨드 서열(seed sequence)로 선정하여, 상기 선정된 씨드 서열을 통하여 ITD를 정확하게 분석함으로써, 이를 통하여 ITD와 관련질환의 진단, 예후진단등을 할 수 있는 방법에 관한 것이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 50.9 | 56.3 |
| Cost of sales | 40.3 | 46.3 |
| Gross profit (loss) | 10.6 | 10.0 |
| Selling, general and administrative expenses | 9.3 | 8.5 |
| Operating income (loss) | 1.3 | 1.6 |
| Non-operating income | 0.1 | 0.2 |
| Other gains | 0.0 | 0.1 |
| Finance income | 0.0 | 0.0 |
| Other | 0.0 | 0.1 |
| Non-operating expenses | 0.3 | 0.4 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.1 | 0.2 |
| Other | 0.2 | 0.1 |
| Profit (loss) before tax | 1.0 | 1.4 |
| Income tax expense | 0.2 | 0.3 |
| Net income (loss) | 0.9 | 1.1 |
Revenue ₩56.3bn, up 10.8% YoY.
Operating margin 2.8% (prior 2.5%).
Net income ₩1.1bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06